v3.26.1
Label Element Value
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND  
Risk/Return: oef_RiskReturnAbstract  
Risk/Return [Heading] oef_RiskReturnHeading Franklin Biotechnology Discovery Fund
Objective [Heading] oef_ObjectiveHeading Investment Goal
Objective, Primary [Text Block] oef_ObjectivePrimaryTextBlock

Capital appreciation.
Expense Heading [Optional Text] oef_ExpenseHeading Fees and Expenses of the Fund
Expense Narrative [Text Block] oef_ExpenseNarrativeTextBlock

These tables describe the fees and expenses that you may pay if you buy, hold and sell shares of the Fund. You may pay other fees (including on Class R6 and Advisor Class shares), such as brokerage commissions and other fees to financial intermediaries, which are not reflected in the tables and examples below. You may qualify for sales charge discounts in Class A if you and your family invest, or agree to invest in the future, at least $25,000 in Franklin Templeton funds and certain other funds distributed through Franklin Distributors, LLC, the Fund’s distributor. More information about these and other discounts is available from your financial professional and under “Your Account” on page 61 in the Fund’s Prospectus and under “Buying and Selling Shares” on page 61 of the Fund’s Statement of Additional Information. In addition, more information about sales charge discounts and waivers for purchases of shares through specific financial intermediaries is set forth in Appendix A – “Intermediary Sales Charge Discounts and Waivers” to the Fund’s prospectus.
Shareholder Fees Caption [Optional Text] oef_ShareholderFeesCaption Shareholder Fees
Operating Expenses Caption [Optional Text] oef_OperatingExpensesCaption Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)
Portfolio Turnover [Heading] oef_PortfolioTurnoverHeading Portfolio Turnover
Portfolio Turnover [Text Block] oef_PortfolioTurnoverTextBlock

The Fund pays transaction costs, such as commissions, when it buys and sells securities (or "turns over" its portfolio). A higher portfolio turnover rate may indicate higher transaction costs and may result in higher taxes when Fund shares are held in a taxable account. These costs, which are not reflected in annual Fund operating expenses or in the Example, affect the Fund's performance. During the most recent fiscal year, the Fund's portfolio turnover rate was 37.62% of the average value of its portfolio.
Portfolio Turnover, Rate oef_PortfolioTurnoverRate 37.62%
Expense Breakpoint Discounts [Text] oef_ExpenseBreakpointDiscounts You may qualify for sales charge discounts in Class A if you and your family invest, or agree to invest in the future, at least $25,000 in Franklin Templeton funds and certain other funds distributed through Franklin Distributors, LLC, the Fund’s distributor.
Expense Breakpoint, Minimum Investment Required [Amount] oef_ExpenseBreakpointMinimumInvestmentRequiredAmount $ 25,000
Expense Example [Heading] oef_ExpenseExampleHeading Example
Expense Example Narrative [Text Block] oef_ExpenseExampleNarrativeTextBlock

This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The Example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your shares at the end of the period. The Example also assumes that your investment has a 5% return each year and that the Fund's operating expenses remain the same. The Example reflects adjustments made to the Fund's operating expenses due to the fee waivers and/or expense reimbursements by management for the 1 Year numbers only. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
Expense Example, No Redemption, By Year, Caption [Text] oef_ExpenseExampleNoRedemptionByYearCaption If you do not sell your shares:
Strategy [Heading] oef_StrategyHeading Principal Investment Strategies
Strategy Narrative [Text Block] oef_StrategyNarrativeTextBlock

Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Fund’s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. In addition to its investments in biotechnology companies, the Fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. The Fund is a "non-diversified" fund, which means it generally invests a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The Fund may invest a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with market capitalizations of less than $2 billion at the time of the Fund’s investment.

The Fund anticipates that, under normal conditions, it will invest more of its assets in U.S. securities than in securities of any other single country. It is currently anticipated that the Fund’s investments in foreign securities will not exceed 20% of its total assets. The Fund may buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The investment manager is a research driven, fundamental investor, pursuing a growth strategy. As a "bottom-up" investor focusing primarily on individual securities, the investment manager seeks companies that have identifiable drivers of future earnings growth and that present, in the investment manager's opinion, the best trade-off between that potential earnings growth, business and financial risk, and valuation. Also, in seeking sustainable growth characteristics, the investment manager looks for companies that it believes can produce sustainable earnings growth and cash flow growth or the potential to generate income.
Summary of Definition of Rule 35d-1 Term in Fund Name [Text Block] fnd_NmRule35d1TermDfnSmryTextBlock The Fund predominantly invests in equity securities. For the Fund’s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. In addition to its investments in biotechnology companies, the Fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. The Fund is a "non-diversified" fund, which means it generally invests a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.
Rule 35d-1 Eighty Percent Investment Policy [Text Block] fnd_NmRule35d1EightyPctInvstmntPlcyTextBlock Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms
Strategy Portfolio Concentration [Text] oef_StrategyPortfolioConcentration Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms.
Bar Chart and Performance Table [Heading] oef_BarChartAndPerformanceTableHeading Performance
Performance Narrative [Text Block] oef_PerformanceNarrativeTextBlock

The following bar chart and table provide some indication of the risks of investing in the Fund. The bar chart shows changes in the Fund's performance from year to year for Class A shares. The table shows how the Fund's average annual returns for 1 year, 5 years, 10 years or since inception, as applicable, compared with those of a broad measure of market performance and additional indexes with characteristics relevant to the Fund. The Fund's past performance (before and after taxes) is not necessarily an indication of how the Fund will perform in the future. You can obtain updated performance information at www.franklintempleton.com or by calling (800) DIAL BEN/342-5236.

Sales charges are not reflected in the bar chart, and if those charges were included, returns would be less than those shown.

Performance Availability Phone [Text] oef_PerformanceAvailabilityPhone (800) DIAL BEN/342-5236
Performance Availability Website Address [Text] oef_PerformanceAvailabilityWebSiteAddress franklintempleton.com
Performance Past Does Not Indicate Future [Text] oef_PerformancePastDoesNotIndicateFuture The Fund's past performance (before and after taxes) is not necessarily an indication of how the Fund will perform in the future.
Bar Chart [Heading] oef_BarChartHeading Class A Annual Total Returns
Bar Chart Does Not Reflect Sales Loads [Text] oef_BarChartDoesNotReflectSalesLoads Sales charges are not reflected in the bar chart, and if those charges were included, returns would be less than those shown.
Bar Chart Closing [Text Block] oef_BarChartClosingTextBlock
   

Best Quarter:

2025, Q3

29.50%

Worst Quarter:

2016, Q1

-24.51%

 

As of June 30, 2026, the Fund’s year-to-date return was 19.47%.
Performance Table Heading oef_PerformanceTableHeading Average Annual Total Returns (figures reflect sales charges) For periods ended December 31, 2025
Index No Deduction for Fees, Expenses, or Taxes [Text] oef_IndexNoDeductionForFeesExpensesTaxes (index reflects no deduction for fees, expenses or taxes)
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Principal Risks  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Principal Risks

You could lose money by investing in the Fund. Mutual fund shares are not deposits or obligations of, or guaranteed or endorsed by, any bank, and are not

insured by the Federal Deposit Insurance Corporation, the Federal Reserve Board, or any other agency of the U.S. government.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Risk Lose Money [Member]  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock You could lose money by investing in the Fund.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Risk Not Insured [Member]  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock Mutual fund shares are not deposits or obligations of, or guaranteed or endorsed by, any bank, and are not

insured by the Federal Deposit Insurance Corporation, the Federal Reserve Board, or any other agency of the U.S. government.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Biotechnology Industry  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Biotechnology Industry: The biotechnology industry is affected by government regulatory requirements, regulatory approval for new drugs and medical products, patent considerations, product liability, and similar matters. In addition, this industry is characterized by competition and rapid technological developments which may make a company’s products or services obsolete in a short period of time. In the past, the biotechnology sector has experienced considerable volatility in reaction to research and other business developments which may affect only one, or a few companies within the sector. The market values of investments in the biotechnology industry are often based upon speculation and expectations about future products, research progress, and new product filings. In addition, a biotechnology company's valuation can be severely affected if a company's product proves to be unsafe, ineffective or unprofitable. Also, there may be a thin trading market in biotechnology securities, which could make the securities difficult to sell at an advantageous time.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Concentration  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Concentration: To the extent the Fund concentrates in a specific industry, a group of industries, sector or type of investment, the Fund will carry much greater risks of adverse developments and price movements in such industries, sectors or investments than a fund that invests in a wider variety of industries, sectors or investments. There is also the risk that the Fund will perform poorly during a slump in demand for securities of companies in such industries or sectors.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Market  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Market: The market values of securities or other investments owned by the Fund will go up or down, sometimes rapidly or unpredictably. The market value of a security or other investment may be reduced by market activity or other results of supply and demand unrelated to the issuer. This is a basic risk associated with all investments. When there are more sellers than buyers, prices tend to fall. Likewise, when there are more buyers than sellers, prices tend to rise. In addition, the value of the Fund’s investments may go up or down due to general market or other conditions that are not specifically related to a particular issuer, such as: real or perceived adverse economic changes, including widespread liquidity issues and defaults in one or more industries; changes in interest, inflation or exchange rates; unexpected natural and man-made world events, such as diseases or disasters; financial, political or social disruptions, including terrorism and war; and U.S. trade disputes or other disputes with specific countries that could result in additional tariffs, trade barriers and/or investment restrictions in certain securities in those countries. Any of these conditions can adversely affect the economic prospects of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen.

Ongoing or threatened armed conflicts throughout the world have caused and could continue to cause significant market disruptions and volatility. The hostilities

and sanctions resulting from those hostilities could have a significant adverse impact on certain investments of the Fund as well as the Fund’s performance and liquidity.

Stock prices tend to go up and down more dramatically than those of debt securities. A slower-growth or recessionary economic environment could have an adverse effect on the prices of the various stocks held by the Fund.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Growth Style Investing  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Growth Style Investing: Growth stock prices reflect projections of future earnings or revenues, and can, therefore, fall dramatically if the company fails to meet those projections. Growth stocks may be more expensive relative to their current earnings or assets compared to value or other stocks, and if earnings growth expectations moderate, their valuations may return to more typical norms, causing their stock prices to fall. Prices of these companies’ securities may be more volatile than other securities, particularly over the short term. In addition, investment styles can go in and out of favor, which could cause additional volatility in the prices of the Fund’s portfolio holdings.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Small Capitalization Companies  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Small Capitalization Companies: Securities issued by small capitalization companies may be more volatile in price than those of larger companies and may involve substantial risks. Such risks may include greater sensitivity to economic conditions, less certain growth prospects, lack of depth of management and funds for growth and development, and limited or less developed product lines and markets. In addition, small capitalization companies may be particularly affected by interest rate increases, as they may find it more difficult to borrow money to continue or expand operations, or may have difficulty in repaying any loans. The markets for securities issued by small capitalization companies also tend to be less liquid than the markets for securities issued by larger companies.

FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Foreign Securities (non-U.S.)  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Foreign Securities (non-U.S.): Investing in foreign securities typically involves different risks than investing in U.S. securities, including risks related to currency exchange rates and policies, country or government specific issues, less favorable trading practices or regulation and greater price volatility. Certain of these risks also may apply to securities of U.S. companies with significant foreign operations. The risks of investing in foreign securities are typically greater in less developed or emerging market countries.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Liquidity  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Liquidity: The trading market for a particular security or type of security or other investments in which the Fund invests may become less liquid or even illiquid. Reduced liquidity will have an adverse impact on the Fund’s ability to sell such securities or other investments when necessary to meet the Fund’s liquidity needs, which may arise or increase in response to a specific economic event or because the investment manager wishes to purchase particular investments or believes that a higher level of liquidity would be advantageous. Reduced liquidity will also

generally lower the value of such securities or other investments. Market prices for such securities or other investments may be relatively volatile.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Non-Diversification  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Non-Diversification: Because the Fund is non-diversified, it may be more sensitive to economic, business, political or other changes affecting individual issuers or investments than a diversified fund, which may negatively impact the Fund's performance and result in greater fluctuation in the value of the Fund’s shares.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Management  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Management: The Fund is subject to management risk because it is an actively managed investment portfolio. The Fund's investment manager applies investment techniques and risk analyses in making investment decisions for the Fund, but there can be no guarantee that these decisions will produce the desired results.

As an actively managed investment portfolio, the Fund’s investments do not track its benchmark. Overweighting investments in an industry or group of industries relative to the Fund’s benchmark increases the risk that the Fund will underperform its benchmark because a general decline in the prices of stocks in that industry or group of industries will affect the Fund to a greater extent than its benchmark. Price declines may result from factors that adversely affect a particular industry or group of industries, such as labor shortages or increased production costs, competitive conditions, or negative investor perceptions. Conversely, if the Fund underweights its investment in an industry or group of industries relative to the Fund’s benchmark, the Fund will participate in any general increase in the prices of stocks in that industry or group of industries to a lesser extent than the Fund’s benchmark.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Cybersecurity  
Risk/Return: oef_RiskReturnAbstract  
Risk [Text Block] oef_RiskTextBlock

Cybersecurity: Cybersecurity incidents, both intentional and unintentional, may allow an unauthorized party to gain access to Fund assets, Fund or customer data (including private shareholder information), or proprietary information, cause the Fund, the investment manager, and/or their service providers (including, but not limited to, Fund accountants, custodians, sub-custodians, transfer agents and financial intermediaries) to suffer data breaches, data corruption or loss of operational functionality or prevent Fund investors from purchasing, redeeming or exchanging shares or receiving distributions. The investment manager has limited ability to prevent or mitigate cybersecurity incidents affecting third party service providers, and such third party service providers may have limited indemnification obligations to the Fund or the investment manager. Cybersecurity incidents may result in financial losses to the Fund and its shareholders, and substantial costs may be incurred in an effort to prevent or mitigate future cybersecurity incidents. Issuers of securities in which the Fund invests are also subject to cybersecurity risks, and the value of these securities could decline if the issuers experience cybersecurity incidents.

Because technology is frequently changing (including the development of artificial intelligence and machine learning), new ways to carry out cyber attacks are always

developing. Therefore, there is a chance that some risks have not been identified or prepared for, or that an attack may not be detected, which puts limitations on the Fund's ability to plan for or respond to a cyber attack. Like other funds and business enterprises, the Fund, the investment manager, and their service providers are subject to the risk of cyber incidents occurring from time to time. The rapid development and increasingly widespread use of artificial intelligence technologies could increase the effectiveness of cyber attacks and exacerbate the risks.
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Russell 3000® Index  
Risk/Return: oef_RiskReturnAbstract  
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel Russell 3000® Index
Average Annual Return, Percent oef_AvgAnnlRtrPct 17.15%
Average Annual Return, Percent oef_AvgAnnlRtrPct 13.15%
Average Annual Return, Percent oef_AvgAnnlRtrPct 14.28%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | NASDAQ Biotechnology Index  
Risk/Return: oef_RiskReturnAbstract  
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel NASDAQ Biotechnology Index
Average Annual Return, Percent oef_AvgAnnlRtrPct 32.40%
Average Annual Return, Percent oef_AvgAnnlRtrPct 3.70%
Average Annual Return, Percent oef_AvgAnnlRtrPct 4.89%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | S&P 500® Index  
Risk/Return: oef_RiskReturnAbstract  
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel S&P 500® Index
Average Annual Return, Percent oef_AvgAnnlRtrPct 17.88%
Average Annual Return, Percent oef_AvgAnnlRtrPct 14.43%
Average Annual Return, Percent oef_AvgAnnlRtrPct 14.82%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | CLASS A  
Risk/Return: oef_RiskReturnAbstract  
Maximum Sales Charge Imposed on Purchases (as a percentage of Offering Price) oef_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 5.50%
Maximum Deferred Sales Charge (as a percentage of Offering Price) oef_MaximumDeferredSalesChargeOverOfferingPrice 0.00% [1]
Management Fees (as a percentage of Assets) oef_ManagementFeesOverAssets 0.61%
Distribution and Service (12b-1) Fees oef_DistributionAndService12b1FeesOverAssets 0.25%
Other Expenses (as a percentage of Assets): oef_OtherExpensesOverAssets 0.16%
Expenses (as a percentage of Assets) oef_ExpensesOverAssets 1.02%
Fee Waiver or Reimbursement oef_FeeWaiverOrReimbursementOverAssets (0.01%) [2]
Net Expenses (as a percentage of Assets) oef_NetExpensesOverAssets 1.01%
Fee Waiver or Reimbursement over Assets, Date of Termination oef_FeeWaiverOrReimbursementOverAssetsDateOfTermination August 31, 2027
Expense Example, with Redemption, 1 Year oef_ExpenseExampleYear01 $ 647
Expense Example, with Redemption, 3 Years oef_ExpenseExampleYear03 855
Expense Example, with Redemption, 5 Years oef_ExpenseExampleYear05 1,081
Expense Example, with Redemption, 10 Years oef_ExpenseExampleYear10 $ 1,728
Year to Date Return, Label [Optional Text] oef_YearToDateReturnLabel As of June 30, 2026, the Fund’s year-to-date return was 19.47%.
Bar Chart, Year to Date Return, Date oef_BarChartYearToDateReturnDate Jun. 30, 2026
Bar Chart, Year to Date Return oef_BarChartYearToDateReturn 19.47%
Highest Quarterly Return, Label [Optional Text] oef_HighestQuarterlyReturnLabel Best Quarter
Highest Quarterly Return, Date oef_BarChartHighestQuarterlyReturnDate Sep. 30, 2025
Highest Quarterly Return oef_BarChartHighestQuarterlyReturn 29.50%
Lowest Quarterly Return, Label [Optional Text] oef_LowestQuarterlyReturnLabel Worst Quarter
Lowest Quarterly Return, Date oef_BarChartLowestQuarterlyReturnDate Mar. 31, 2016
Lowest Quarterly Return oef_BarChartLowestQuarterlyReturn (24.51%)
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel Return before taxes
Average Annual Return, Percent oef_AvgAnnlRtrPct 43.92%
Average Annual Return, Percent oef_AvgAnnlRtrPct 4.96%
Average Annual Return, Percent oef_AvgAnnlRtrPct 6.35%
Annual Return [Percent] oef_AnnlRtrPct (17.16%)
Annual Return [Percent] oef_AnnlRtrPct 18.80%
Annual Return [Percent] oef_AnnlRtrPct (15.72%)
Annual Return [Percent] oef_AnnlRtrPct 34.84%
Annual Return [Percent] oef_AnnlRtrPct 29.89%
Annual Return [Percent] oef_AnnlRtrPct (17.70%)
Annual Return [Percent] oef_AnnlRtrPct (12.66%)
Annual Return [Percent] oef_AnnlRtrPct 18.40%
Annual Return [Percent] oef_AnnlRtrPct 4.00%
Annual Return [Percent] oef_AnnlRtrPct 52.30%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | CLASS A | After Taxes on Distributions  
Risk/Return: oef_RiskReturnAbstract  
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel Return after taxes on distributions
Average Annual Return, Percent oef_AvgAnnlRtrPct 40.17%
Average Annual Return, Percent oef_AvgAnnlRtrPct 3.19%
Average Annual Return, Percent oef_AvgAnnlRtrPct 4.51%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | CLASS A | After Taxes on Distributions and Sales  
Risk/Return: oef_RiskReturnAbstract  
Average Annual Return, Label [Optional Text] oef_AverageAnnualReturnLabel Return after taxes on distributions and sale of Fund shares
Average Annual Return, Percent oef_AvgAnnlRtrPct 27.96%
Average Annual Return, Percent oef_AvgAnnlRtrPct 3.37%
Average Annual Return, Percent oef_AvgAnnlRtrPct 4.45%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Class C  
Risk/Return: oef_RiskReturnAbstract  
Maximum Sales Charge Imposed on Purchases (as a percentage of Offering Price) oef_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 0.00%
Maximum Deferred Sales Charge (as a percentage of Offering Price) oef_MaximumDeferredSalesChargeOverOfferingPrice 1.00%
Management Fees (as a percentage of Assets) oef_ManagementFeesOverAssets 0.61%
Distribution and Service (12b-1) Fees oef_DistributionAndService12b1FeesOverAssets 1.00%
Other Expenses (as a percentage of Assets): oef_OtherExpensesOverAssets 0.16%
Expenses (as a percentage of Assets) oef_ExpensesOverAssets 1.77%
Fee Waiver or Reimbursement oef_FeeWaiverOrReimbursementOverAssets (0.01%) [2]
Net Expenses (as a percentage of Assets) oef_NetExpensesOverAssets 1.76%
Fee Waiver or Reimbursement over Assets, Date of Termination oef_FeeWaiverOrReimbursementOverAssetsDateOfTermination August 31, 2027
Expense Example, with Redemption, 1 Year oef_ExpenseExampleYear01 $ 279
Expense Example, with Redemption, 3 Years oef_ExpenseExampleYear03 557
Expense Example, with Redemption, 5 Years oef_ExpenseExampleYear05 959
Expense Example, with Redemption, 10 Years oef_ExpenseExampleYear10 1,887
Expense Example, No Redemption, 1 Year oef_ExpenseExampleNoRedemptionYear01 179
Expense Example, No Redemption, 3 Years oef_ExpenseExampleNoRedemptionYear03 557
Expense Example, No Redemption, 5 Years oef_ExpenseExampleNoRedemptionYear05 959
Expense Example, No Redemption, 10 Years oef_ExpenseExampleNoRedemptionYear10 $ 1,887
Average Annual Return, Percent oef_AvgAnnlRtrPct 50.17%
Average Annual Return, Percent oef_AvgAnnlRtrPct 5.39%
Average Annual Return, Percent oef_AvgAnnlRtrPct 6.17%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | Class R6  
Risk/Return: oef_RiskReturnAbstract  
Maximum Sales Charge Imposed on Purchases (as a percentage of Offering Price) oef_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 0.00%
Maximum Deferred Sales Charge (as a percentage of Offering Price) oef_MaximumDeferredSalesChargeOverOfferingPrice 0.00%
Management Fees (as a percentage of Assets) oef_ManagementFeesOverAssets 0.61%
Distribution and Service (12b-1) Fees oef_DistributionAndService12b1FeesOverAssets 0.00%
Other Expenses (as a percentage of Assets): oef_OtherExpensesOverAssets 0.17%
Expenses (as a percentage of Assets) oef_ExpensesOverAssets 0.78%
Fee Waiver or Reimbursement oef_FeeWaiverOrReimbursementOverAssets (0.11%) [2]
Net Expenses (as a percentage of Assets) oef_NetExpensesOverAssets 0.67%
Fee Waiver or Reimbursement over Assets, Date of Termination oef_FeeWaiverOrReimbursementOverAssetsDateOfTermination August 31, 2027
Expense Example, with Redemption, 1 Year oef_ExpenseExampleYear01 $ 68
Expense Example, with Redemption, 3 Years oef_ExpenseExampleYear03 238
Expense Example, with Redemption, 5 Years oef_ExpenseExampleYear05 422
Expense Example, with Redemption, 10 Years oef_ExpenseExampleYear10 $ 955
Average Annual Return, Percent oef_AvgAnnlRtrPct 52.85%
Average Annual Return, Percent oef_AvgAnnlRtrPct 6.55%
Average Annual Return, Percent oef_AvgAnnlRtrPct 7.36%
FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | ADVISOR CLASS  
Risk/Return: oef_RiskReturnAbstract  
Maximum Sales Charge Imposed on Purchases (as a percentage of Offering Price) oef_MaximumSalesChargeImposedOnPurchasesOverOfferingPrice 0.00%
Maximum Deferred Sales Charge (as a percentage of Offering Price) oef_MaximumDeferredSalesChargeOverOfferingPrice 0.00%
Management Fees (as a percentage of Assets) oef_ManagementFeesOverAssets 0.61%
Distribution and Service (12b-1) Fees oef_DistributionAndService12b1FeesOverAssets 0.00%
Other Expenses (as a percentage of Assets): oef_OtherExpensesOverAssets 0.16%
Expenses (as a percentage of Assets) oef_ExpensesOverAssets 0.77%
Fee Waiver or Reimbursement oef_FeeWaiverOrReimbursementOverAssets (0.01%) [2]
Net Expenses (as a percentage of Assets) oef_NetExpensesOverAssets 0.76%
Fee Waiver or Reimbursement over Assets, Date of Termination oef_FeeWaiverOrReimbursementOverAssetsDateOfTermination August 31, 2027
Expense Example, with Redemption, 1 Year oef_ExpenseExampleYear01 $ 78
Expense Example, with Redemption, 3 Years oef_ExpenseExampleYear03 245
Expense Example, with Redemption, 5 Years oef_ExpenseExampleYear05 427
Expense Example, with Redemption, 10 Years oef_ExpenseExampleYear10 $ 954
Average Annual Return, Percent oef_AvgAnnlRtrPct 52.68%
Average Annual Return, Percent oef_AvgAnnlRtrPct 6.42%
Average Annual Return, Percent oef_AvgAnnlRtrPct 7.22%
[1]

There is a 1% contingent deferred sales charge that applies to investments of $1 Million or more (see "Investments of $1 Million or More" under "Choosing a Share Class") and purchases by certain retirement plans without an initial sales charge on shares sold within 18 months of purchase.
[2] The investment manager has agreed to reduce its fees to reflect reduced services resulting from the Fund’s investments in Franklin Templeton affiliated funds. In addition, the transfer agency fees on Class R6 shares of the Fund have been capped so that transfer agency fees for that class do not exceed 0.03%. These contractual arrangements are expected to continue until August 31, 2027. During the terms, the fee waiver and expense reimbursement agreements may not be terminated or amended without approval of the board of trustees except to add series or classes, to reflect the extension of termination dates or to lower the waiver and expense limitation (which would result in lower fees for shareholders).